drugset / Trial / NCT04518501
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
NaSequentialOpen-labelTreatment
Summary
Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes. To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in platinum-resistance relapsed Ovarian cancer patients.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2024-12-03
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 150 mg | Oral |
| Subject | arsenic trioxide | Small molecule | 0.27 unknown | Oral |
Indications
No indication recorded.